Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 exon 14 ins |
| Therapy | Azacitidine + Gilteritinib + Venetoclax |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Azacitidine + Gilteritinib + Venetoclax | Phase Ib/II | Actionable | In a Phase I/II trial, Venclexta (venetoclax), Vidaza (azacitidine), and Xospata (gilteritinib) treatment demonstrated safety in acute myeloid leukemia patients with FLT3-ITD or FLT3 D835 mutations and led to a combined complete remission (CR)/CR with incomplete hematologic recovery (CR/CRi) rate of 96% and a median relapse-free survival and median overall survival not reached in newly diagnosed patients (n=30), and a CR/CRi rate of 27% in relapsed/refractory patients (n=22) (PMID: 38277619; NCT04140487). | 38277619 |
| FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Azacitidine + Gilteritinib + Venetoclax | Clinical Study | Actionable | In a retrospective analysis, real-world treatment with Xospata (gilteritinib), Venclexta (venetoclax), and Vidaza (azacitidine) resulted in a modified composite complete remission rate (mCRc) of 62.1% (18/29) and a 2-yr overall survival (OS) rate of 60.9% in acute myeloid leukemia patients with FLT3-ITD and/or TKD mutations, with an mCRc of 70% (7/10) and a 1-yr OS rate of 80% in patients without prior FLT3 TKI, and an mCRc of 57.9% (11/19) and a 1-yr OS rate of 58.8% with prior FLT3 TKI (PMID: 39180903). | 39180903 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38277619) | Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. | Full reference... |
| (39180903) | Triplet therapy with gilteritinib, venetoclax, and azacitidine for relapsed/refractory FLT3mut acute myeloid leukemia. | Full reference... |